PMID- 34159090
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220424
IS  - 2223-4691 (Print)
IS  - 2223-4691 (Electronic)
IS  - 2223-4683 (Linking)
VI  - 10
IP  - 5
DP  - 2021 May
TI  - Neoadjuvant combination of pazopanib or axitinib and programmed cell death 
      protein-1-activated dendritic cell-cytokine-induced killer cells immunotherapy 
      may facilitate surgery in patients with renal cell carcinoma.
PG  - 2091-2102
LID - 10.21037/tau-21-406 [doi]
AB  - BACKGROUND: Radical/cytoreductive nephrectomy or nephron-sparing surgery may be 
      thought to be not safe or unfeasible in some renal cell carcinoma (RCC) patients 
      in which tumor is locally advanced or highly complicated. Neoadjuvant therapy may 
      reduce the volume of the tumor, thus facilitates surgery. The aim the study is to 
      evaluate the efficacy and safety of neoadjuvant combination of pazopanib or 
      axitinib and PD-1-activated dendritic cell-cytokine-induced killer (PD-1/DC-CIK) 
      cell immunotherapy in those patients. METHODS: Data from 16 RCC patients who 
      received neoadjuvant pazopanib (Group P, n=9) or axitinib (Group A, n=7) plus 
      PD-1/DC-CIK cells immunotherapy were reviewed retrospectively. A total of 9 
      participants that were potential candidates for radical/cytoreductive nephrectomy 
      (RN/CN) had locally advanced tumor and 5 participants with partial nephrectomy 
      (PN) absolute indications had highly complicated tumors. The efficacy outcomes 
      were based on volume changes of the primary tumor, lymph nodes, and tumor 
      thrombus in 13 participants with complete computed tomography (CT) imaging. The 
      treatment-related toxicities and surgical complications were also reported. 
      RESULTS: With a median of 2.1 months treatment, the overall volume of the tumors 
      decreased by a median of 42.30% [interquartile range (IQR): 19.37-66.78%]. 
      Specifically, the median reduction of tumor volume was 88.77 and 15.50 cm(3) in 
      group P and group A, respectively (P=0.014). However, participants in Group P 
      were more likely to experience grade 3 or 4 treatment-related adverse events 
      (AEs) than those in Group A (44.4% vs. 0). Finally, all participants were 
      candidates for appropriate surgery after neoadjuvant therapy (as assessed by the 
      surgeon), and 10 participants accepted surgery, including 5 PN, 4 RN/CN, and 1 
      lymph node dissection. A solitary participant had Clavien grade IV acute renal 
      failure required dialysis and another had grade II lymphatic leakage. 
      CONCLUSIONS: Neoadjuvant combination of pazopanib or axitinib and PD-1/DC-CIK 
      cells immunotherapy was well-tolerated and could effectively reduce the volume of 
      tumors in locally advanced or highly complicated RCC patients.
CI  - 2021 Translational Andrology and Urology. All rights reserved.
FAU - Zhang, Zhiling
AU  - Zhang Z
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
AD  - State Key Laboratory of Oncology in Southern China, Guangzhou, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
FAU - Xiong, Longbin
AU  - Xiong L
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
AD  - State Key Laboratory of Oncology in Southern China, Guangzhou, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
FAU - Wu, Zeshen
AU  - Wu Z
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
AD  - State Key Laboratory of Oncology in Southern China, Guangzhou, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
FAU - Liu, Huiming
AU  - Liu H
AD  - State Key Laboratory of Oncology in Southern China, Guangzhou, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
AD  - Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China.
FAU - Ning, Kang
AU  - Ning K
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
AD  - State Key Laboratory of Oncology in Southern China, Guangzhou, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
FAU - Peng, Yulu
AU  - Peng Y
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
AD  - State Key Laboratory of Oncology in Southern China, Guangzhou, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
FAU - Yu, Chunping
AU  - Yu C
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
AD  - State Key Laboratory of Oncology in Southern China, Guangzhou, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
FAU - Ding, Ya
AU  - Ding Y
AD  - State Key Laboratory of Oncology in Southern China, Guangzhou, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
AD  - Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
FAU - Weng, Desheng
AU  - Weng D
AD  - State Key Laboratory of Oncology in Southern China, Guangzhou, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
AD  - Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
FAU - Xia, Jianchuan
AU  - Xia J
AD  - State Key Laboratory of Oncology in Southern China, Guangzhou, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
AD  - Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
FAU - Jiang, Lijuan
AU  - Jiang L
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
AD  - State Key Laboratory of Oncology in Southern China, Guangzhou, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
FAU - Guo, Shengjie
AU  - Guo S
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
AD  - State Key Laboratory of Oncology in Southern China, Guangzhou, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
FAU - Han, Hui
AU  - Han H
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
AD  - State Key Laboratory of Oncology in Southern China, Guangzhou, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
FAU - Zhou, Fangjian
AU  - Zhou F
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
AD  - State Key Laboratory of Oncology in Southern China, Guangzhou, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
FAU - Dong, Pei
AU  - Dong P
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
AD  - State Key Laboratory of Oncology in Southern China, Guangzhou, China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Transl Androl Urol
JT  - Translational andrology and urology
JID - 101581119
PMC - PMC8185689
OTO - NOTNLM
OT  - Neoadjuvant
OT  - PD-1/DC-CIK cells immunotherapy
OT  - axitinib
OT  - pazopanib
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/tau-21-406). The authors have no 
      conflicts of interest to declare.
EDAT- 2021/06/24 06:00
MHDA- 2021/06/24 06:01
PMCR- 2021/05/01
CRDT- 2021/06/23 07:22
PHST- 2021/06/23 07:22 [entrez]
PHST- 2021/06/24 06:00 [pubmed]
PHST- 2021/06/24 06:01 [medline]
PHST- 2021/05/01 00:00 [pmc-release]
AID - tau-10-05-2091 [pii]
AID - 10.21037/tau-21-406 [doi]
PST - ppublish
SO  - Transl Androl Urol. 2021 May;10(5):2091-2102. doi: 10.21037/tau-21-406.